US · INTS
Intensity Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Westport, CT 06880
- Website
- intensitytherapeutics.com
Price · as of 2024-12-31
$5.19
Market cap 14.45M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | $133.50 | ||||
| 2024 | $55.25 |
AI valuation
Our deep-learning model estimates Intensity Therapeutics, Inc.'s (INTS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.19
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| INTS | Intensity Therapeutics, I… | $5.19 | 14.45M | — | — | — | — | -1.89 | 10.53 | — | -1.74 | — | 10.53 | 0.00% | — | — | -202.34% | 3350.51% | -147.37% | 0.05 | — | 1.92 | 1.48 | 0.15 | -1522.00% | — | 11124.00% | -49.52% | -8.67 | 3074.75% | 0.00% | 0.00% | 0.00% | -1.71 | -1.86 | — | -20.70 |
| ANTX | AN2 Therapeutics, Inc. | $1.10 | 30.14M | — | — | — | — | -0.76 | 0.48 | — | -13.78 | — | 0.48 | 0.00% | — | — | -49.69% | -697.76% | -44.47% | 0.00 | — | 8.43 | 8.20 | -6.60 | -3723.00% | — | -756.00% | -126.06% | -4.81 | -630.01% | 0.00% | 0.00% | 14.60% | 0.82 | 0.90 | — | -1.80 |
| BOLD | Boundless Bio, Inc. | $1.16 | 25.97M | — | — | — | — | -0.44 | 0.19 | — | 1.18 | -0.60 | 0.19 | 0.00% | — | — | -554.86% | 73.46% | -38.87% | 0.32 | — | 18.98 | 18.70 | -0.33 | 7342.00% | — | 3346.00% | -220.80% | -7.48 | 63.54% | 0.00% | 0.00% | 0.00% | 1.03 | 1.20 | — | -1.38 |
| IBIO | iBio, Inc. | $2.82 | 44.53M | +1,048% | -88% | — | — | -0.48 | 0.59 | 22.05 | -0.22 | — | 1.10 | 100.00% | -4650.50% | -4594.25% | -101.52% | -174.01% | -70.79% | 0.24 | -87.75 | 1.59 | 1.42 | 0.30 | -7308.00% | 7778.00% | -1835.00% | -173.71% | -2.51 | -143.31% | 0.00% | 0.00% | 0.00% | -0.20 | -0.24 | 9.36 | -21.87 |
| ITRM | Iterum Therapeutics plc | $0.26 | 13.97M | — | — | — | — | -1.10 | -6.66 | — | -2.24 | — | -1.14 | 0.00% | — | — | 472.61% | -628.33% | -69.93% | -11.16 | — | 1.41 | 1.37 | -0.99 | -5743.00% | — | -3195.00% | -98.48% | -1.52 | -899.75% | 0.00% | 0.00% | 0.00% | -2.60 | -1.82 | — | -16.11 |
| NXTC | NextCure, Inc. | $12.72 | 34.09M | — | — | — | — | -0.38 | 0.32 | — | 0.77 | — | 0.32 | 0.00% | — | — | -61.87% | -769.60% | -53.28% | 0.09 | — | 7.50 | 7.20 | 0.40 | -1168.00% | — | -2326.00% | -196.82% | -4.26 | -531.71% | 0.00% | 0.00% | 72.95% | 0.70 | 1.01 | — | -7.28 |
| PLUR | Pluri Inc. | $3.60 | 29.39M | +873% | -44% | — | — | -1.37 | -4.65 | 23.81 | -2.05 | — | -2.49 | 48.95% | -1659.88% | -1690.34% | 689.30% | -701.84% | -59.46% | -4.98 | -25.40 | 0.68 | 0.66 | -1.28 | -1078.00% | 30982.00% | 810.00% | -62.33% | -0.56 | -627.70% | 0.00% | 0.00% | 0.00% | -2.04 | -2.28 | 33.87 | -17.73 |
| PSTV | Plus Therapeutics, Inc. | $0.30 | 18.31M | +20,855% | +1,192% | — | — | -0.80 | -1.16 | 1.79 | -1.21 | — | -1.06 | 85.37% | -252.32% | -222.84% | 252.07% | 197.13% | -144.03% | -0.38 | -3.95 | 0.34 | 0.27 | -0.39 | -4481.00% | 1854.00% | -1776.00% | -102.64% | -0.68 | 143.54% | 0.00% | 0.00% | 3.59% | -0.69 | -0.95 | 1.75 | -112.05 |
| QTTB | Q32 Bio Inc. | $4.56 | 56.11M | +726% | — | — | — | -0.57 | 4.77 | — | 0.71 | — | 4.77 | 0.00% | — | — | 53.86% | 62.63% | -68.49% | 3.33 | -220.34 | 4.97 | 4.77 | 1.30 | -6060.00% | -10000.00% | 26286.00% | -250.34% | -4.11 | 64.23% | 0.00% | 0.00% | 311.27% | 0.48 | 0.47 | — | -4.89 |
| RLYB | Rallybio Corporation | $7.54 | 39.81M | — | — | — | — | -0.56 | 0.53 | 50.94 | 0.55 | — | 0.53 | 100.00% | -9511.95% | -9084.12% | -68.85% | 1714.74% | -62.89% | 0.00 | — | 10.87 | 10.50 | 0.23 | -2772.00% | — | -1824.00% | -152.12% | -7.90 | 1396.88% | 0.00% | 0.00% | 0.00% | 0.54 | 0.67 | -51.82 | -4.85 |
| SONN | Sonnet BioTherapeutics Ho… | $1.26 | 8.43M | +87,488% | -33% | — | +67,885% | -0.19 | -2.83 | 73.88 | -0.12 | — | -2.83 | 100.00% | -63617.91% | -39929.30% | 2089.93% | 846.19% | -181.38% | -0.27 | — | 0.66 | 0.28 | 0.00 | -9218.00% | -8740.00% | -6049.00% | -625.56% | -2.68 | 614.69% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 72.88 | -73.78 |
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
- CEO
- Lewis H. Bender
- Employees
- 5
- Beta
- 4.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.19) − 1 = — (DCF, example).